Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Clinical significance of pharmacokinetic drug interactions between interferon-alpha and antineoplastic drugs
Autore:
Czejka, MJ; Schueller, J; Kletzl, H; Strauch, S; Pietrzak, C;
Indirizzi:
Univiaienna, Pharmacokinet Dept, Inst Pharmaceut Chem, A-1090 Vienna, Austr Univ Vienna Vienna Austria A-1090 Pharmaceut Chem, A-1090 Vienna, Austr Hosp Rudolfstiftung, Dept Internal Med & Oncol 1, Vienna, Austria Hosp Rudolfstiftung Vienna Austria ernal Med & Oncol 1, Vienna, Austria
Titolo Testata:
BIODRUGS
fascicolo: 2, volume: 11, anno: 1999,
pagine: 87 - 101
SICI:
1173-8804(199902)11:2<87:CSOPDI>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
PHASE-II TRIAL; TRANS-RETINOIC ACID; ADVANCED MALIGNANT-MELANOMA; ADVANCED COLORECTAL-CANCER; ACUTE PROMYELOCYTIC LEUKEMIA; ADVANCED BREAST-CANCER; CELL LUNG-CANCER; CHRONIC MYELOGENOUS LEUKEMIA; EPITHELIAL OVARIAN-CANCER; BLOOD-PLASMA LEVELS;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
179
Recensione:
Indirizzi per estratti:
Indirizzo: Czejka, MJ Univ Vienna, Pharmacokinet Dept, Inst Pharmaceut Chem, Althanstr 14, A-1090 Univ Vienna Althanstr 14 Vienna Austria A-1090 nstr 14, A-1090
Citazione:
M.J. Czejka et al., "Clinical significance of pharmacokinetic drug interactions between interferon-alpha and antineoplastic drugs", BIODRUGS, 11(2), 1999, pp. 87-101

Abstract

The major problems in chemotherapy are occasional low response rates in patients despite favourable in vitro action, the development of drug resistance and long or short term adverse effects. Therefore, in the past decade efforts have been made to circumvent these problems by combining antineoplastic drugs with biomodulating or cytoprotective agents. Most of the clinically useful drug regimens consist of a cocktail of drugs with different mechanisms of action, and hence different toxicity profiles. Dose-limiting factors in regard to toxicity and efficacy predominate, and it is therefore clinically essential to know whether or not a pharmacokinetic drug interaction occurs. The introduction of interferon-alpha (IFN alpha) in chemotherapy is an alternative investigational approach to amplify the cytotoxicity of an antineoplastic drug in order to increase tumour response. Most of the clinical studies reported with IFN alpha provide useful information and identify major pharmacodynamic interactions, but only a few focus on and report potential pharmacokinetic interactions between antineoplastic drugs and IFN alpha in patients. The broad spectrum of antineoplastic drugs whose activity can be enhanced by IFN alpha argues for multiple levels of drug-drug interactions:protein binding (cisplatin), alteration in cellular uptake, modulation of drug target enzymes (dihydropyrimidine hydrogenase) and changes in biotransformation (tretinoin) or excretion. Pharmacokinetic and/or pharmacodynamic interactions may be beneficial (fluorouracil) or sometimes detrimental and coincidental (doxorubicin). This article focuses on observed pharmacokinetic drug interactions betweenIFN alpha and antineoplastic drugs and discusses possible mechanisms of action.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/09/20 alle ore 08:03:15